Chapter-2

Recent Insights of Molecular Approaches to Study Brain Tumor Associated Seizure and Epilepsy

Author

Dr. Rajesh Kumar Kar
Department of Neurosurgery,
School of Medicine,
Yale University, USA.
E-mail: rajesh9632@iitbombay.org, rajesh.kar@yale.edu;

Abstract

Brain tumor-associated seizures and epilepsy (BTAE) represent a significant clinical challenge, other than Temporal Lobe Epilepsy and other epilepsies or seizures, impacting both patient quality of life and treatment outcomes. Recent advances in molecular approaches have provided valuable insights into the underlying mechanisms of these neurological disorders, offering new avenues for diagnosis, treatment, and management. Here an overview of the latest research findings and methodologies in molecular studies of brain tumor seizure and epilepsy is presented. The use of lower to higher model organisms, brain tumor induced epilepsy models, genomic and proteomic techniques, cellular and molecular heterogeneity, chromatin modifications, post-translational modifications, kinase signaling pathways, and cellular metabolism in unraveling the complex pathophysiology of BTAE is discussed. Additionally, the implications of these molecular insights for the development of targeted therapies and precision medicine approaches, as well as future directions for research in this field are explored.

****

1. INTRODUCTION

Brain tumor-associated seizures and epilepsy (BTAE) represent a multifaceted clinical phenomenon (1), characterized by spontaneous seizures in patients with brain tumors (2-5). These seizures not only impact patient quality of life but also pose challenges in diagnosis, treatment, and management(6). Understanding the molecular mechanisms underlying brain tumor seizures and epilepsy is essential for developing effective therapeutic strategies and improving patient outcomes(7, 8). In recent years, molecular approaches have emerged as powerful tools for unraveling the complex pathophysiology of these neurological disorders(3, 9-17).

Here a comprehensive overview of recent insights gained from molecular studies of BTAE is discussed. The clinical significance and impact of these disorders, highlighting the need for innovative research approaches to address the challenges they present are discussed and then outline of various molecular methodologies and approaches used to study BTAE is covered.

One key area of focus is the use of model organisms, ranging from simple organisms like yeast to more complex vertebrate models such as rodents and primates(18, 19). These model systems offer unique advantages for studying specific aspects of BTAE, including genetic manipulation, high-throughput screening, and the ability to recapitulate key features of the disease.

Next, it delves into genomic and proteomic approaches that have revolutionized our understanding of the molecular landscape of brain tumors and epileptogenesis(14, 20, 21). These techniques allow researchers to identify genetic alterations, protein expression patterns, and molecular signatures associated with BTAE, providing valuable insights into disease mechanisms and potential therapeutic targets.

Furthermore, it explores the role of cellular and molecular heterogeneity within brain tumors and their microenvironment in driving epileptogenesis and seizure susceptibility. It discusses how chromatin modifications (22-31), post-translational modifications(32, 33), kinase signaling pathways(34-38), and cellular metabolism(39) contribute to the pathophysiology of BTAE.

Overall, the molecular approach in greater detail is presented, highlighting recent advancements and their implications for understanding and treating BTAE. By integrating data from various molecular studies, it aims to offer a comprehensive understanding of BTAE, paving the way for innovative treatments and improved patient care.

2. LOWER TO HIGHER MODEL ORGANISM FOR MOLECULAR STUDIES IN BTAE

The use of model organisms spanning from lower to higher species has been instrumental in elucidating the molecular mechanisms underlying BTAE (40).

- Studies in virus (41) to yeast provide fundamental insights into molecular pathways implicated in BTAE, laying the groundwork for further investigations in higher organisms.
- Invertebrate models allow researchers to study basic neuronal functions, synaptic transmission, and the genetic basis of neurological disorders, including epilepsy.
- Zebrafish serve as powerful vertebrate models for studying brain development, neural circuitry, and disease modeling.
- Zebrafish embryos are transparent, allowing for real-time visualization of brain development and seizure activity (42).
- Studies in Drosophila have revealed conserved signaling pathways, such as the PI3K-Akt-mTOR pathway, implicated in both brain tumors and epilepsy (43).
- Genetic and chemical screens in zebrafish models facilitate the discovery of novel genes and pathways involved in BTAE.
- Transgenic and knockout rodent models enable researchers to manipulate specific genes implicated in brain tumor formation and epileptogenesis.
- Rodent models allow for detailed behavioral, electrophysiological, and imaging studies of seizure activity and its modulation by brain tumors (44).
- Non-human primates provide the closest resemblance to human brain anatomy, physiology, and behavior.
- Primate models offer unique insights into complex cognitive functions, seizure propagation, and the impact of brain tumors on higher-order brain regions (45).
- While less frequently used due to ethical considerations and cost, primate models are invaluable for translational research and preclinical testing of therapeutic interventions.
- Human-derived models, including patient-derived tumor xenografts and induced pluripotent stem cell (iPSC)-derived neuronal cultures, provide a direct link to human disease pathology (46). Patient-derived xenograft models implanted into immunocompromised mice retain key features of the original tumor microenvironment, allowing for the study of tumor growth, invasion, and response to therapy. iPSC-derived neuronal cultures derived from patient samples offer a platform for studying the

effects of specific genetic mutations on neuronal function and network activity.

Integrating findings across multiple model organisms facilitates translational research and improves the likelihood of successful clinical outcomes for patients with BTAE.

3. DRUG INDUCED AND OTHER APPROCHES USED TO STUDY BTAE

Here are various models used to study BTAE, including chemical, thermal, mechanical, and other models:

1. **Chemical-Induced Models**
   - **N-Ethyl-N-Nitrosourea (ENU) Models:** Administration of ENU induces brain tumors, including gliomas, in rodents (47). These tumors can lead to epilepsy.
   - **3-Nitropropionic Acid (3-NP) Models:** 3-NP administration can induce oxidative stress and excitotoxicity, leading to epileptogenesis in animal models.
   - **Alkylating Agents:** Various alkylating agents like temozolomide, used in chemotherapy, have been studied to induce tumors and epilepsy in animal models.

2. **Thermal-Induced Models**
   - **Laser-Induced Thermal Models:** Laser ablation techniques can be used to induce localized thermal damage to brain tissue, mimicking aspects of tumor growth and causing epileptic activity.

3. **Mechanical-Induced Models**
   - **Implantation of Tumor Cells:** Tumor cells obtained from either animals or humans can be implanted directly into the brain tissue of animals to induce tumor growth and associated epilepsy.
   - **Stereotactic Injection Models:** Injection of tumor-inducing agents or genetically modified cells into specific brain regions can be performed to induce tumor formation and epilepsy.

4. **Genetic Models**
   - **Genetically Engineered Mouse Models (Gemms):** These models involve altering specific genes related to tumor formation or epilepsy to study their role in the development of BTAE.

- **Transgenic Models:** Animals expressing mutated genes associated with brain tumors (PTEN, TP53) can develop tumors and epileptic seizures, providing insights into the underlying mechanisms (48).

5. **Patient-Derived Xenograft Models**
   - Xenografting human tumor tissues into immunodeficient mice allows researchers to study the interaction between human tumor cells and the host microenvironment, including the development of epilepsy.

6. **Combined Models**
   - Some studies combine different induction methods (chemical, mechanical, genetic) to better replicate the complexity of human BTAE and its underlying mechanisms.

These models offer valuable tools for understanding the pathophysiology of BTAE.

4. GENOMICS AND PROTEOMICS APPROCHES TO STUDY BTAE

Genomics and proteomics have revolutionized our understanding of the molecular mechanisms underlying BTAE. Genomic studies have identified genetic alterations that contribute to tumor development and epileptogenesis. High-throughput sequencing techniques, such as whole-genome sequencing (WGS) and whole-exome sequencing (WES)(49), have uncovered recurrent mutations in genes involved in cell cycle regulation (TP53, CDKN2A/B), growth factor signaling (EGFR, PDGFRA), and chromatin remodeling (ATRX, IDH1/2) in various types of BTAE.

Proteomics approaches complement genomics by characterizing the protein expression profiles and signaling pathways dysregulated in BTAE. Mass spectrometry-based proteomics enables the identification and quantification of proteins involved in tumor growth, invasion, and response to therapy. Proteomic studies have revealed aberrant expression of proteins implicated in cell proliferation (Ki-67), angiogenesis (VEGF), and neuronal excitability (ion channels, neurotransmitter receptors) in epileptogenic brain tumors.

Integration of genomic and proteomic data has facilitated the identification of potential therapeutic targets for BTAE.

Genomics Approaches

1. **Whole Genome Sequencing (WGS)**
   - WGS enables comprehensive analysis of the entire genome, allowing identification of genetic mutations, copy number alterations, and structural variations BTAE.
   - In BTAE research, WGS helps elucidate the genetic landscape of tumors, including driver mutations and alterations in genes involved in seizure susceptibility and epileptogenesis.

2. **Whole Exome Sequencing (WES)**
   - WES focuses on sequencing the protein-coding regions of the genome, providing insights into somatic mutations and germline variants implicated in brain tumor development and seizure onset(49).
   - By pinpointing mutations in genes encoding ion channels, neurotransmitter receptors, and signaling molecules, WES aids in understanding the genetic basis of epileptogenesis in the context of brain tumors.

3. **Transcriptomics**
   - Transcriptomic profiling using techniques such as RNA sequencing (RNA-seq) allows for the characterization of gene expression patterns in BTAE.
   - Differential gene expression analysis reveals dysregulated pathways involved in tumor growth, inflammation, and synaptic transmission, shedding light on molecular mechanisms underlying seizure generation and propagation.

4. **Epigenomics**
   - Epigenetic modifications, including DNA methylation and histone modifications, play a crucial role in regulating gene expression in brain tumors and epilepsy (20, 22-24, 28-31, 50, 51).
   - Epigenomic profiling elucidates epigenetic alterations associated with tumor progression and epileptogenicity, offering potential biomarkers and therapeutic targets for intervention.

Proteomics Approaches

1. **Mass Spectrometry (MS)-based Proteomics**
   - MS-based proteomics enables the identification and quantification of proteins in brain tumor tissues and epileptic brain regions (52).
   - Comparative proteomic analyses reveal protein expression changes associated with tumor progression, epileptogenesis, and treatment response, providing mechanistic insights into disease pathogenesis.

2. Protein-Protein Interaction (PPI) Networks

- Computational analysis of PPI networks constructed from proteomic data elucidates molecular pathways and protein complexes dysregulated in brain tumors associated with epilepsy.
- Network-based approaches identify hub proteins and signaling cascades implicated in tumor growth, invasion, and seizure induction, guiding the development of targeted therapies.

3. Single-Cell Proteomics

- Single-cell proteomics technologies enable the characterization of cellular heterogeneity within brain tumors and epileptic brain regions at the protein level.
- Single-cell proteomic profiling identifies cell-type-specific protein expression patterns and signaling pathways dysregulated in epileptogenic foci, facilitating the development of targeted therapies tailored to individual patients.

5. CELL-to-CELL AND MOLECULAR HETEROGENEITY STUDIES IN BTAE

Cell-to-cell and molecular heterogeneity studies have advanced our understanding of yeast cell (53-56) biology to tumor biology and epileptogenesis, revealing distinct subpopulations of tumor cells with diverse genetic, epigenetic, and functional properties.

Single-cell sequencing technologies, such as single-cell RNA sequencing (scRNA-seq) and single-cell ATAC-seq (scATAC-seq), have enabled the characterization of individual tumor cells and their transcriptional and epigenetic profiles. These studies have identified cellular states associated with tumor progression, invasion, and treatment resistance, as well as cell types involved in epileptogenic networks within the tumor microenvironment.

In addition to cellular heterogeneity, molecular heterogeneity at the genetic, epigenetic, and proteomic levels contributes to the diverse clinical manifestations of BTAE. Integrative multi-omics analyses have identified molecular subtypes and dysregulated pathways associated with epileptogenesis and treatment response variability.

1. Cellular Heterogeneity

- **Tumor Microenvironment (TME)**
  - The TME of brain tumors comprises various cell types, including tumor cells, immune cells, stromal cells, and vascular cells.

  - Studying cellular interactions within the TME provides insights into tumor progression, immune evasion, and therapeutic resistance in BTAE.
- **Neuronal and Glial Cell Types**
  - BTAE arise from different cell types, including neurons, astrocytes, oligodendrocytes, and neural stem cells (3, 10).
  - Investigating the cellular origin and heterogeneity of tumor cells and their interactions with surrounding neural and glial cells elucidates the mechanisms underlying epileptogenesis and seizure generation.

2. Molecular Heterogeneity

- **Genetic Alterations**
  - BTAE exhibit genetic heterogeneity, with distinct mutational profiles and copy number alterations (57).
  - Genomic profiling reveals driver mutations, oncogenic pathways, and tumor suppressor gene alterations contributing to tumor growth and epileptogenicity.
- **Gene Expression Signatures**
  - Transcriptomic analyses identify gene expression patterns associated with different tumor subtypes, histological grades, and clinical outcomes (18).
  - Molecular subtyping based on gene expression signatures helps stratify patients with BTAE and predict response to therapy.
- **Epigenetic Modifications**
  - Epigenetic alterations, including DNA methylation patterns and histone modifications, contribute to molecular heterogeneity in BTAE (51, 58).
  - Epigenomic profiling elucidates epigenetic regulatory mechanisms underlying tumor heterogeneity and their impact on epileptogenesis and treatment response.

Methodologies for Studying Heterogeneity

1. Single-Cell Analysis

- Single-cell RNA sequencing (scRNA-seq) and single-cell proteomics enable the characterization of cellular heterogeneity within brain tumors and epileptic brain regions at unprecedented resolution.
- Single-cell analysis identifies rare cell populations, transcriptional states, and cell-to-cell interactions driving tumor progression and epileptogenicity.

2. Spatial Transcriptomics

- Spatial transcriptomic techniques, such as spatially resolved RNA-seq and multiplexed imaging, provide spatial context to gene expression patterns within tumor tissues and epileptic brain regions.
- Spatial profiling reveals spatial heterogeneity in gene expression, cell types, and cellular interactions, offering insights into tumor microenvironment dynamics and epileptogenic foci.

3. Multi-Omics Integration

- Integrating multi-omics data, including genomics, transcriptomics, proteomics, and epigenomics, facilitates comprehensive characterization of tumor heterogeneity and molecular networks.
- Multi-omics integration identifies convergent molecular pathways, biomarkers, and therapeutic targets for personalized treatment strategies in BTAE.

In summary, cell-to-cell and molecular heterogeneity studies play a crucial role in deciphering the complex biology of BTAE.

6. CHROMATIN MODIFICATIONS, POL II MEDIATED TRANSCRIPTIONAL REGULATION AND SPLICING STUDIES IN BTAE

Chromatin modifications and transcriptional regulation play crucial roles in the pathogenesis of BTAE. Epigenetic alterations, including changes in DNA methylation, histone modifications, and chromatin remodeling, have been implicated in tumor development and epileptogenesis. Studies have shown aberrant DNA methylation patterns in genes involved in neuronal excitability, synaptic transmission, and cell cycle regulation in epileptogenic brain tumors. Histone modifications, such as histone acetylation and methylation, can modulate gene expression and influence cellular phenotypes associated with epileptogenicity.

Furthermore, transcriptional regulation mediated by RNA polymerase II (POL II) is dysregulated in BTAE. Genome-wide studies have revealed alterations in POL II-mediated transcriptional programs, leading to aberrant expression of genes involved in cell proliferation, apoptosis, and synaptic plasticity (21, 59). Dysregulated transcriptional networks contribute to tumor growth, invasion, and resistance to therapy, as well as the generation of epileptogenic foci within the tumor microenvironment.

Splicing dysregulation is another hallmark of BTAE and other cancers(60). Alternative splicing events can generate diverse transcript isoforms with distinct functional properties, impacting cellular phenotypes and disease progression (61, 62). Dysregulated splicing factors and splice variants have been implicated in epileptogenic pathways and seizure susceptibility in brain tumors. Understanding the splicing landscape in epileptogenic tumors may uncover novel therapeutic targets for controlling seizures and tumor growth.

1. **Chromatin Modifications**
   - **Histone Acetylation and Methylation**
     - Chromatin modifications, such as histone acetylation and methylation, dynamically regulate gene expression by modulating chromatin structure and accessibility to transcriptional machinery.
     - Dysregulation of histone modifications in BTAE alters the expression of genes involved in tumor growth, invasion, and seizure susceptibility.
   - **DNA Methylation**
     - Aberrant DNA methylation patterns are commonly observed in brain tumors and epileptic brain regions, contributing to gene silencing and genomic instability (30).
     - DNA methylation changes affect the expression of genes implicated in neuronal excitability, synaptic transmission, and inflammation, thereby influencing epileptogenic processes.

2. **Pol II-Mediated Transcriptional Regulation**
   - **Transcription Factor Dysregulation**
     - Alterations in transcription factor activity and expression disrupt the balance of gene regulatory networks in BTAE.
     - Dysregulated transcription factors, such as NF-κB, AP-1, and CREB, modulate the expression of genes involved in inflammation(63), gliosis, and seizure susceptibility.
   - **Enhancer and Promoter Activity**
     - Pol II-mediated transcriptional regulation at enhancer and promoter regions controls the expression of genes critical for tumor growth and epileptogenesis.
     - Enhancer hijacking and promoter activation by oncogenic drivers and transcriptional co-factors contribute to aberrant gene expression in BTAE.

3. **Splicing Studies**
   - **Alternative Splicing Variants**
     - Alternative splicing generates transcript isoforms with diverse functions, contributing to cellular heterogeneity and phenotypic diversity in BTAE.

  - Dysregulated alternative splicing events alter the expression of genes involved in ion channel function, neurotransmitter signaling, and synaptic plasticity, influencing seizure susceptibility (64).
- **Splicing Factor Dysregulation**
  - Dysregulation of splicing factors, such as SF3B1(65), SRSF1 (66), and hnRNPs, disrupts pre-mRNA splicing and mRNA processing in brain tumors and epileptic brain regions.
  - Aberrant splicing factor expression correlates with altered splicing patterns and aberrant protein isoform expression associated with tumor progression and epileptogenesis.

Methodologies for Studying Chromatin Modifications, Transcriptional Regulation, and Splicing

- Chromatin Immunoprecipitation (ChIP) and ChIP-seq for mapping histone modifications and transcription factor binding sites.
- RNA sequencing (RNA-seq) and nascent RNA sequencing (nRNA-seq) for profiling transcriptional activity and Pol II occupancy.
- Splice junction analysis and RNA-seq data analysis pipelines for quantifying alternative splicing events and splice isoform expression.

7. POST TRANSLATIONAL MODIFICATIONS STUDIES IN BTAE

Post-translational modifications (PTMs) play critical roles in regulating protein function and signaling pathways dysregulated in BTAE. PTMs such as phosphorylation, acetylation, hypusination (8, 13, 32, 33),ubiquitination, and glycosylation modulate protein stability, localization, and activity, thereby influencing cellular processes relevant to tumor growth and epileptogenesis.

Phosphorylation, mediated by kinases and phosphatases, is one of the most common PTMs implicated in BTAE.

Acetylation and methylation of histone proteins and non-histone proteins modulate chromatin structure and gene expression in epileptogenic tumors. Dysregulated histone acetylation, mediated by histone acetyltransferases (HATs) and histone deacetylases (HDACs), alters the expression of genes involved in synaptic plasticity, neuronal excitability, and inflammation. Similarly, histone methylation by histone methyltransferases (HMTs) and histone demethylases (HDMs) regulates transcriptional programs implicated in epileptogenesis.

Ubiquitination, glycosylation, and other PTMs also contribute to the molecular pathogenesis of BTAE. Dysregulated ubiquitin-proteasome system (UPS) activity and protein degradation pathways disrupt protein homeostasis and promote tumor growth and seizure susceptibility. Aberrant glycosylation of cell surface receptors and adhesion molecules influences cell-cell interactions and tumor invasion in epileptogenic brain tumors.

Overall, PTMs play multifaceted roles in the molecular pathogenesis of BTAE, offering potential therapeutic targets for controlling seizures and tumor growth.

1. **Acetylation:** Acetylation involves the addition of an acetyl group to lysine residues and is mediated by acetyltransferases. Histone acetylation regulates chromatin structure and gene expression, impacting cellular processes relevant to epilepsy and tumorigenesis, such as cell cycle control, DNA repair, and apoptosis. Dysregulated protein acetylation has been implicated in both epileptogenesis and gliomagenesis (67).

2. **Ubiquitination:** Ubiquitination is the attachment of ubiquitin molecules to target proteins, marking them for degradation by the proteasome or regulating their localization and activity. Dysregulated ubiquitination pathways have been associated with altered protein turnover, disrupted cellular homeostasis, and increased oncogenic signaling in BTAE.

3. **SUMOylation:** Small ubiquitin-like modifier (SUMO) proteins can be conjugated to target proteins, modulating their function, stability, and interactions. SUMOylation has been implicated in the regulation of ion channels, transcription factors, and DNA repair proteins, influencing neuronal excitability, glioma cell proliferation, and response to therapy in BTAE (68).

4. **Glycosylation:** Glycosylation involves the attachment of sugar molecules to proteins, affecting their stability, localization, and activity. Aberrant protein glycosylation has been observed in gliomas and epileptic brain tissue, contributing to tumor invasion, angiogenesis, and neuroinflammation.

5. **Methylation:** Methylation of DNA and histones regulates gene expression patterns in both neurons and glioma cells and by microRNA in other cancers (69). Altered DNA methylation patterns have been associated with changes in the expression of genes involved in epileptogenesis, gliomagenesis, and treatment resistance.

Studies investigating PTMs in BTAE employ various experimental techniques, including mass spectrometry, immunohistochemistry, chromatin immunoprecipitation, and gene expression profiling. By elucidating the role of PTMs in the molecular pathogenesis of BTAE, researchers aim to identify novel therapeutic targets and develop more effective treatment strategies tailored to individual patients' molecular profiles.

8. KINASES, PHOSPATASES AND KINASE TARGETS STUDIES IN BTAE

Kinases and phosphatases are critical regulators of signaling pathways implicated in BTAE. Dysregulation of kinase and phosphatase activity leads to aberrant phosphorylation events, which can drive tumor growth, invasion, and epileptogenesis. Targeting specific kinases and phosphatases and their downstream signaling targets holds promise for developing novel therapeutic strategies for managing BTAE.

Several kinase pathways have been implicated in the pathogenesis of BTAE. The PI3K-Akt-mTOR pathway, frequently dysregulated in gliomas and other brain tumors and other cancers (60, 70), plays a key role in promoting cell survival, proliferation, and metabolism. Hyperactivation of this pathway contributes to tumor growth and epileptogenesis, making it an attractive therapeutic target. Inhibition of mTOR signaling using drugs like rapamycin and its analogs has shown antiepileptic effects in preclinical models and clinical trials.

Other kinase targets implicated in BTAE include receptor tyrosine kinases (RTKs) such as EGFR and PDGFRA, which drive oncogenic signaling cascades promoting tumor growth and seizure generation. Small molecule inhibitors targeting these kinases have shown promise in preclinical studies and are being evaluated in clinical trials for their efficacy in controlling seizures and tumor progression.

Phosphatases, including protein phosphatase 2A (PP2A) and protein tyrosine phosphatases (PTPs), counterbalance kinase activity by dephosphorylating proteins involved in cell signaling pathways. Dysregulated phosphatase activity contributes to the hyperactivation of kinase signaling pathways in BTAE. Restoring phosphatase function or targeting specific phosphatases may provide alternative therapeutic strategies for controlling seizures and tumor growth.

Furthermore, kinase-targeted therapies are being explored in combination with other treatment modalities, such as radiation therapy and chemotherapy, to

enhance their efficacy in managing BTAE. Combinatorial approaches targeting multiple signaling pathways may overcome resistance mechanisms and improve treatment outcomes in patients with refractory epilepsy.

Overall, elucidating the role of kinases, phosphatases, and their downstream targets in BTAE is essential for developing precision therapies that target the molecular drivers of both tumor growth and seizure generation.

1. **Kinases:** Kinases are enzymes that catalyze the transfer of phosphate groups from ATP to specific target molecules, typically proteins, in a process called phosphorylation. In the context of BTAE, dysregulated kinase activity can contribute to aberrant signaling pathways, neuronal hyperexcitability, and seizure generation. Identifying overactive kinases or those involved in promoting tumor growth and epileptogenesis can provide insights into potential therapeutic interventions (34-37, 71-73).

2. **Phosphatases:** Phosphatases, on the other hand, are enzymes that catalyze the removal of phosphate groups from proteins through dephosphorylation. They play a crucial role in regulating cellular signaling pathways by counteracting the actions of kinases. Dysregulation of phosphatase activity can also contribute to aberrant signaling cascades and neuronal dysfunction seen in BTAE. Understanding the balance between kinase and phosphatase activity is essential for deciphering the molecular mechanisms underlying epileptogenesis.

3. **Kinase Targets:** Kinases phosphorylate a wide range of target proteins involved in various cellular processes, including cell growth, survival, differentiation, and synaptic transmission. In the context of BTAE, identifying specific kinase targets that contribute to seizure generation or tumor progression is critical for developing targeted therapies. These targets may include ion channels, neurotransmitter receptors, synaptic proteins, and transcription factors implicated in epileptogenesis and tumor growth.

By elucidating the dysregulated signaling pathways and molecular alterations driving epileptogenesis in the context of brain tumors, researchers aim to identify novel therapeutic targets and develop more effective treatments for epilepsy associated with these tumors.

9. CELLULAR METABOLISM STUDIES IN BTAE

Cellular metabolism plays a critical role in the pathogenesis of BTAE. Dysregulated metabolism, characterized by altered glucose utilization, mitochondrial dysfunction, and aberrant nutrient sensing, contributes to tumor

growth, invasion, and epileptogenesis. Understanding the metabolic reprogramming of tumor cells and their interactions with the surrounding microenvironment is essential for developing novel therapeutic strategies for managing BTAE(39).

One hallmark of BTAE is increased glucose uptake and glycolytic flux, known as the Warburg effect. Tumor cells preferentially metabolize glucose via glycolysis, even in the presence of oxygen(60), leading to the accumulation of lactate and acidification of the tumor microenvironment. This metabolic shift supports tumor growth and provides energy substrates for sustained proliferation and seizure generation.

In addition to glycolysis, alterations in mitochondrial metabolism contribute to the pathogenesis of epileptogenic brain tumors. Mitochondrial dysfunction, characterized by impaired oxidative phosphorylation and increased reactive oxygen species (ROS) production, disrupts cellular bioenergetics and redox homeostasis, further promoting tumor growth and epileptogenesis. Targeting mitochondrial metabolism and redox signaling pathways may offer therapeutic opportunities for controlling seizures and tumor progression.

Furthermore, dysregulated nutrient sensing pathways, such as the mechanistic target of rapamycin (mTOR) and AMP-activated protein kinase (AMPK) pathways, play crucial roles in coordinating cellular metabolism and growth in BTAE. Hyperactivation of mTOR signaling promotes protein synthesis, cell proliferation, and epileptogenesis, while AMPK activation inhibits mTOR activity and promotes catabolic processes such as autophagy and lipid oxidation(38).

Therapeutic strategies targeting cellular metabolism in BTAE aim to exploit metabolic vulnerabilities while minimizing toxicity to normal brain tissue. Inhibitors of glycolysis, mitochondrial metabolism, and nutrient sensing pathways are being evaluated as potential antiepileptic drugs and adjuvant therapies for controlling seizures and tumor growth. Combinatorial approaches targeting multiple metabolic pathways may offer synergistic effects and improve treatment outcomes in patients with refractory epilepsy.

Overall, elucidating the complex interplay between cellular metabolism and epileptogenesis in brain tumors provides insights into novel therapeutic targets and treatment strategies for managing seizures and tumor progression.

Here are some key aspects of cellular metabolism studied in the context of BTAE:

1. **Aerobic Glycolysis (Warburg Effect):** Many brain tumors, including gliomas, exhibit a metabolic phenotype characterized by increased glucose uptake and lactate production even in the presence of oxygen, a phenomenon known as the Warburg effect. This metabolic reprogramming provides rapid energy production and biosynthetic precursors necessary for tumor growth and proliferation. Dysregulated aerobic glycolysis can also contribute to neuronal hyperexcitability and seizure generation by altering local metabolic microenvironments and neurotransmitter dynamics.

2. **Glutamate Metabolism:** Glutamate is the major excitatory neurotransmitter in the brain, and its metabolism is tightly regulated to maintain neuronal excitability within physiological limits. Dysregulated glutamate metabolism in brain tumors can lead to excessive glutamate release, synaptic excitotoxicity, and seizure activity. Glutamate excitotoxicity is implicated in both epileptogenesis and gliomagenesis, highlighting the complex interplay between neuronal and glial metabolism in BTAE (10-12).

3. **Mitochondrial Dysfunction:** Mitochondria play a central role in cellular metabolism, energy production, and redox balance. Dysfunctional mitochondria in brain tumors can impair oxidative phosphorylation, leading to energy depletion, increased reactive oxygen species (ROS) production, and altered cellular signaling. Mitochondrial dysfunction contributes to both tumor progression and epileptogenesis by disrupting neuronal and glial energy metabolism and promoting oxidative stress-mediated damage.

4. **Ketone Metabolism:** Ketone bodies, such as β-hydroxybutyrate and acetoacetate, are alternative energy substrates produced during fasting or ketogenic diets. Emerging evidence suggests that ketone metabolism may provide neuroprotective effects and alleviate seizure activity in BTAE by restoring metabolic homeostasis, enhancing mitochondrial function, and modulating neurotransmitter release. Ketogenic therapies have shown promising results in preclinical and clinical studies as adjuvant treatments for both epilepsy and glioma patients(74).

5. **Redox Metabolism:** Redox metabolism, including antioxidant defense mechanisms and ROS scavenging pathways, plays a critical role in maintaining cellular redox balance and protecting against oxidative stress-induced damage. Dysregulated redox metabolism in brain tumors can disrupt cellular homeostasis, promote DNA damage and genomic instability, and contribute to tumor progression and epileptogenesis.

Targeting redox pathways represents a potential therapeutic strategy for managing BTAE by modulating oxidative stress responses and sensitizing tumor cells to therapy.

By elucidating the metabolic adaptations and vulnerabilities of BTAE, researchers aim to identify novel therapeutic targets and develop personalized treatment strategies to improve patient outcomes and quality of life.

10. SURGICAL APPROACHES AND ANTIEPILEPTIC DRUGS TO TARGET BTAE

Surgery plays a pivotal role in the management of BTAE, aiming to achieve maximal tumor resection while preserving neurological function and controlling seizures. Resective surgery, including gross total resection (GTR) or subtotal resection (STR) of the tumor and surrounding epileptogenic tissue, offers the potential for long-term seizure control and improved survival outcomes. Advanced neuroimaging techniques, such as functional MRI (fMRI) and intraoperative electrocorticography (ECoG), aid in identifying epileptogenic zones and guiding surgical resection to minimize postoperative deficits.

In cases where complete resection is not feasible due to tumor location or involvement of eloquent brain regions, surgical techniques such as laser interstitial thermal therapy (LITT) and stereotactic radiosurgery (SRS) offer minimally invasive alternatives. LITT utilizes laser energy to ablate tumor tissue while sparing adjacent healthy brain tissue, providing a precise treatment option for deep-seated or inoperable tumors. SRS delivers high-dose radiation to the tumor with submillimeter accuracy, inducing tumor cell death and reducing seizure burden.

Antiepileptic drugs (AEDs) are routinely used as adjunctive therapy to manage seizures in patients with BTAE. Traditional AEDs such as phenytoin, carbamazepine, and valproate are commonly prescribed to control seizures perioperatively and in the postoperative period. However, newer generation AEDs like levetiracetam and lamotrigine are preferred due to their favorable side effect profiles and reduced drug interactions.

Combining surgical resection with targeted molecular therapies offers a multimodal approach to treating BTAE. Molecularly targeted therapies, such as inhibitors of the PI3K-Akt-mTOR pathway or receptor tyrosine kinase inhibitors, may complement surgical resection by targeting residual tumor cells and reducing the risk of tumor recurrence and seizure recurrence.

In conclusion, surgical resection remains the cornerstone of treatment for BTAE, offering the potential for long-term seizure control and improved quality of life. Combinatorial approaches integrating surgery, targeted molecular therapies, and antiepileptic drugs hold promise for optimizing treatment outcomes and addressing the complex interplay between tumor biology and epileptogenesis(75).

Here's an overview of surgical strategies and AED therapies targeting BTAE (76):

1. **Surgical Resection:** Surgical resection of the brain tumor is often the primary treatment approach for managing tumor-associated epilepsy, especially when the tumor is localized and accessible without causing significant neurological deficits. The goal of surgery is to remove as much of the tumor as possible while preserving neurological function and controlling seizures. Complete or near-complete resection of the tumor can lead to significant reduction or elimination of seizures in many patients.

2. **Awake Craniotomy:** In cases where the tumor is located in or near eloquent brain regions responsible for critical functions such as language or motor control, awake craniotomy techniques may be employed. This approach allows the surgeon to map functional areas of the brain in real-time while the patient is awake, minimizing the risk of postoperative neurological deficits while maximizing tumor resection.

3. **Stereotactic Radiosurgery (Srs):** Stereotactic radiosurgery delivers highly focused radiation beams to target the tumor, sparing surrounding healthy tissue. While primarily used for small, deep-seated, or surgically inaccessible tumors, SRS can also be an option for controlling tumor-associated seizures, particularly in cases where surgery is not feasible or when residual tumor remains after resection.

4. **Electrophysiological Monitoring:** Intraoperative electrocorticography (ECoG) and intraoperative neurophysiological monitoring (IONM) techniques may be employed during surgery to identify epileptogenic zones and functional brain regions. This helps guide the surgical approach and minimize the risk of postoperative seizures or neurological deficits.

5. **Antiepileptic Drugs (Aeds):** AEDs are commonly used as adjunctive therapy to control seizures in patients with brain tumors, both before and after surgical intervention. The choice of AED depends on factors such as seizure type, patient characteristics, drug interactions, and potential side effects. AEDs commonly used in the management of BTAE include levetiracetam, lacosamide, carbamazepine, and others (77).

6. **Chemotherapeutic Agents:** Chemotherapy is a standard treatment for brain tumors, and certain chemotherapeutic agents may also have antiepileptic effects. Preclinical studies often involve testing the efficacy of chemotherapeutic agents in reducing seizure frequency and tumor growth in animal models of BTAE(78).
    - Temozolomide, lomustine, and vincristine are examples of chemotherapeutic agents investigated for their potential antiepileptic properties (79).

7. **Antineoplastic Agents**
    - Antineoplastic agents target tumor cells and may indirectly affect seizure activity by reducing tumor burden and associated inflammation.
    - In research studies, antineoplastic agents are evaluated for their ability to suppress tumor growth and mitigate seizure activity in animal models.
    - Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is an example of an antineoplastic agent investigated for its effects on both tumor progression and seizure control (80).

8. **Immunotherapies**
    - Immunotherapies harness the immune system to target tumor cells and modulate inflammatory responses associated with epilepsy.
    - Preclinical research explores the efficacy of immunotherapeutic approaches, such as immune checkpoint inhibitors and chimeric antigen receptor (CAR) T cell therapy, in controlling tumor growth and reducing seizure frequency.
    - Checkpoint inhibitors (pembrolizumab, nivolumab) and adoptive T cell therapy represent promising avenues for immunotherapy in BTAE.

9. **Non-Invasive Neuromodulation**
    - Non-invasive neuromodulation techniques, such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), offer potential therapeutic benefits for epilepsy.
    - Research efforts focus on optimizing stimulation parameters and identifying patient populations most likely to benefit from neuromodulation therapy.
    - Non-invasive neuromodulation may complement traditional pharmacological and surgical approaches in the management of drug-resistant BTAE (80).

10. Preclinical Imaging And Biomarkers

- Preclinical imaging modalities, including magnetic resonance imaging (MRI), positron emission tomography (PET), and electroencephalography (EEG), enable the assessment of tumor progression and seizure activity in animal models.
- Biomarkers, such as circulating tumor DNA (ctDNA) and inflammatory cytokines, provide insights into disease progression and treatment response in preclinical studies.
- Integrating preclinical imaging and biomarker analysis enhances our understanding of the relationship between brain tumors and epilepsy and informs the development of novel therapeutic strategies.

11. **Targeted Therapies:** In addition to traditional AEDs, there is growing interest in targeted therapies that specifically address the molecular mechanisms underlying tumor-associated epilepsy. For example, drugs targeting the PI3K-Akt-mTOR pathway, which is frequently dysregulated in certain types of BTAE, have shown promise in preclinical and clinical studies for controlling seizures. Examples include EGFR inhibitors (e.g., erlotinib), mTOR inhibitors (everolimus), and histone deacetylase inhibitors (vorinostat)(81).

12. **Multimodal Treatment Approaches:** Multimodal treatment approaches that combine surgery, radiation therapy, chemotherapy, and AEDs may be necessary for optimal management of BTAE, particularly in cases of high-grade or recurrent tumors. These approaches aim to achieve maximal tumor control while minimizing seizure frequency and improving overall patient outcomes.

These approaches not only elucidate the underlying mechanisms of seizure generation but also inform the development of targeted therapies and personalized treatment strategies for patients with this challenging neurological condition.

11. FUTURE PROSPECTS

The future of managing BTAE lies in advancing precision medicine approaches tailored to individual patient profiles. Integrating genomic, proteomic, and metabolic profiling techniques will enable the identification of patient-specific molecular targets and personalized therapeutic strategies. Furthermore, the development of novel imaging modalities and biomarkers for early detection and monitoring of tumor progression and treatment response will enhance clinical decision-making and prognostication.

Advancements in neurosurgical techniques, including minimally invasive approaches and intraoperative imaging technologies, will continue to improve surgical outcomes and reduce morbidity associated with tumor resection. Moreover, the integration of neurostimulation techniques such as responsive neurostimulation (RNS) and deep brain stimulation (DBS) may offer alternative treatment options for patients with refractory epilepsy.

Emerging therapies targeting immune checkpoints, tumor microenvironment, and tumor metabolism hold promise for overcoming treatment resistance and improving long-term outcomes in patients with BTAE. Collaborative multidisciplinary efforts across neurosurgery, neuro-oncology, neurology, and molecular biology will be essential for translating these advancements into clinical practice and improving patient care.

Here are some recent insights and prospects in this field:

1. **Genomic and Transcriptomic Profiling:** Advances in high-throughput sequencing technologies have enabled comprehensive genomic and transcriptomic profiling of brain tumors and epileptic tissues. This has led to the identification of various genetic alterations and gene expression patterns associated with tumor-associated seizures and epilepsy. Understanding these molecular signatures can provide insights into disease mechanisms and potential therapeutic targets.

2. **Identification of Driver Mutations:** By analyzing the genomic landscape of brain tumors and epileptic tissues, researchers have identified specific driver mutations and molecular pathways implicated in seizure generation and epileptogenesis. Targeting these driver mutations or dysregulated pathways with precision therapies could potentially suppress seizures and improve epilepsy management.

3. **Molecular Classification:** Molecular profiling has facilitated the subclassification of brain tumors and epilepsies based on their underlying molecular features rather than just histological characteristics. This molecular classification allows for more accurate diagnosis, prognosis, and personalized treatment strategies tailored to individual patients.

4. **Biomarker Discovery:** Molecular studies have identified potential biomarkers associated with seizure occurrence, recurrence, and drug responsiveness in brain tumor patients with epilepsy. These biomarkers could aid in early diagnosis, monitoring disease progression, predicting treatment responses, and developing novel therapeutic approaches.

5. **Targeted Therapies:** Molecular insights into the signaling pathways involved in BTAE have paved the way for the development of targeted therapies. For example, drugs targeting specific molecular alterations such as mutations in the PI3K-Akt-mTOR pathway have shown promise in preclinical and clinical studies for controlling seizures in patients with certain types of brain tumors and epilepsies.

6. **Immunotherapy:** Emerging evidence suggests that immunotherapy approaches, including immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy, may have potential in treating brain tumors and associated seizures by harnessing the immune system to target tumor cells. Molecular profiling can help identify patients who are most likely to benefit from these immunotherapeutic strategies.

7. **Drug Repurposing:** Molecular studies have identified existing drugs targeting specific molecular pathways that could be repurposed for treating BTAE. Drug repurposing offers a cost-effective and time-efficient strategy to rapidly translate molecular insights into clinical applications.

Overall, molecular approaches to studying BTAE are opening new avenues for understanding the underlying pathophysiology and developing innovative therapeutic interventions. Continued research efforts in this area are essential for improving patient outcomes and quality of life.

12. CONCLUDING REMARK

Understanding and treating BTAE represent a dynamic and evolving field, bridging oncology, neurology, and pharmacology. As research continues to unravel the complex interplay between tumors and neuronal circuits, the future promises more targeted and effective strategies for managing both tumor growth and epilepsy, ultimately improving patient outcomes.

In conclusion, the management of BTAE requires a comprehensive and multidisciplinary approach, integrating surgical resection, targeted molecular therapies, and antiepileptic drugs. Advances in precision medicine, neurosurgical techniques, and therapeutic modalities offer hope for improved seizure control, tumor management, and patient outcomes. By continuing to innovate and collaborate, we can strive towards personalized and effective treatments for this complex neurological condition.

REFERENCES

[1] Dupont S. 2008. [Epilepsy and brain tumors]. Rev Neurol (Paris) 164:517-22.

[2] Lamba N, Catalano PJ, Cagney DN, Haas-Kogan DA, Bubrick EJ, Wen PY, Aizer AA. 2021. Seizures Among Patients With Brain Metastases: A Population- and Institutional-Level Analysis. Neurology 96:e1237-e1250.

[3] Becker AJ, Blümcke I, Urbach H, Hans V, Majores M. 2006. Molecular neuropathology of epilepsy-associated glioneuronal malformations. J Neuropathol Exp Neurol 65:99-108.

[4] Lieu AS, Howng SL. 2000. Intracranial meningiomas and epilepsy: incidence, prognosis and influencing factors. Epilepsy Res 38:45-52.

[5] Pallud J, Audureau E, Blonski M, Sanai N, Bauchet L, Fontaine D, Mandonnet E, Dezamis E, Psimaras D, Guyotat J, Peruzzi P, Page P, Gal B, Párraga E, Baron MH, Vlaicu M, Guillevin R, Devaux B, Duffau H, Taillandier L, Capelle L, Huberfeld G. 2014. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 137:449-62.

[6] Vacher E, Rodriguez Ruiz M, Rees JH. 2023. Management of brain tumour related epilepsy (BTRE): a narrative review and therapy recommendations. Br J Neurosurg doi:10.1080/02688697.2023.2170326:1-8.

[7] Seidel S, Wehner T, Miller D, Wellmer J, Schlegel U, Grönheit W. 2022. Brain tumor related epilepsy: pathophysiological approaches and rational management of antiseizure medication. Neurol Res Pract 4:45.

[8] Kar RK. 2023. Comparative Studies of Mesial Temporal Lobe Epilepsy with Epilepsy from Brain Tumors, p 18. *In* Dubey SRKSKNK (ed), Socio-Scientific Interaction in Diabetes and Cancer and Its Management, 1st ed doi:10.9734/bpi/mono/978-81-968135-7-4/CH3. B P International, India.

[9] de Lanerolle NC, Kim JH, Williamson A, Spencer SS, Zaveri HP, Eid T, Spencer DD. 2003. A retrospective analysis of hippocampal pathology in human temporal lobe epilepsy: evidence for distinctive patient subcategories. Epilepsia 44:677-87.

[10] Eid T, Lee TW, Patrylo P, Zaveri HP. 2019. Astrocytes and Glutamine Synthetase in Epileptogenesis. J Neurosci Res 97:1345-1362.

[11] Eid T, Thomas MJ, Spencer DD, Rundén-Pran E, Lai JC, Malthankar GV, Kim JH, Danbolt NC, Ottersen OP, de Lanerolle NC. 2004. Loss of glutamine synthetase in the human epileptogenic hippocampus: possible mechanism for raised extracellular glutamate in mesial temporal lobe epilepsy. Lancet 363:28-37.

[12] Eid T, Williamson A, Lee TS, Petroff OA, de Lanerolle NC. 2008. Glutamate and astrocytes--key players in human mesial temporal lobe epilepsy? Epilepsia 49 Suppl 2:42-52.

[13] Kar RK, Hanner AS, Starost MF, Springer D, Mastracci TL, Mirmira RG, Park MH. 2021. Neuron-specific ablation of eIF5A or deoxyhypusine synthase leads to impairments in growth, viability, neurodevelopment, and cognitive functions in mice. J Biol Chem 297:101333.

[14] Mirza N, Appleton R, Burn S, du Plessis D, Duncan R, Farah JO, Feenstra B, Hviid A, Josan V, Mohanraj R, Shukralla A, Sills GJ, Marson AG, Pirmohamed M. 2017. Genetic regulation of gene expression in the epileptic human hippocampus. Hum Mol Genet 26:1759-1769.

[15] Sugawara T, Kaneko S. 2014. [Genetic diagnosis for epilepsy]. Nihon Rinsho 72:834-8.

[16] Vezzani A, Balosso S, Ravizza T. 2012. Inflammation and epilepsy. Handb Clin Neurol 107:163-75.

[17] Ziegler A, Steindl K, Hanner AS, Kar RK, Prouteau C, Boland A, Deleuze JF, Coubes C, Bézieau S, Küry S, Maystadt I, Le Mao M, Lenaers G, Navet B, Faivre L, Tran Mau-

Them F, Zanoni P, Chung WK, Rauch A, Bonneau D, Park MH. 2022. Bi-allelic variants in DOHH, catalyzing the last step of hypusine biosynthesis, are associated with a neurodevelopmental disorder. Am J Hum Genet 109:1549-1558.
[18] Lee TS, Li AY, Rapuano A, Mantis J, Eid T, Seyfried TN, de Lanerolle NC. 2021. Gene expression in the epileptic (EL) mouse hippocampus. Neurobiol Dis 147:105152.
[19] Zavileyskiy LG, Aleshin VA, Kaehne T, Karlina IS, Artiukhov AV, Maslova MV, Graf AV, Bunik VI. 2022. The Brain Protein Acylation System Responds to Seizures in the Rat Model of PTZ-Induced Epilepsy. Int J Mol Sci 23.
[20] Sánchez-Carpintero Abad R, Sanmartí Vilaplana FX, Serratosa Fernández JM. 2007. Genetic causes of epilepsy. Neurologist 13:S47-51.
[21] van Loo KMJ, Becker AJ. 2019. Transcriptional Regulation of Channelopathies in Genetic and Acquired Epilepsies. Front Cell Neurosci 13:587.
[22] Hauser RM, Henshall DC, Lubin FD. 2018. The Epigenetics of Epilepsy and Its Progression. Neuroscientist 24:186-200.
[23] Henshall DC. 2018. Epigenetic changes in status epilepticus. Epilepsia 59 Suppl 2:82-86.
[24] Henshall DC, Kobow K. 2015. Epigenetics and Epilepsy. Cold Spring Harb Perspect Med 5.
[25] Itoh M, Yamashita M, Kaneko M, Okuno H, Abe M, Yamazaki M, Natsume R, Yamada D, Kaizuka T, Suwa R, Sakimura K, Sekiguchi M, Wada K, Hoshino M, Mishina M, Hayashi T. 2018. Deficiency of AMPAR-Palmitoylation Aggravates Seizure Susceptibility. J Neurosci 38:10220-10235.
[26] Kobow K, Blümcke I. 2011. The methylation hypothesis: do epigenetic chromatin modifications play a role in epileptogenesis? Epilepsia 52 Suppl 4:15-9.
[27] Kobow K, Blümcke I. 2012. The emerging role of DNA methylation in epileptogenesis. Epilepsia 53 Suppl 9:11-20.
[28] Kobow K, Blümcke I. 2014. Epigenetic mechanisms in epilepsy. Prog Brain Res 213:279-316.
[29] Kobow K, Blümcke I. 2018. Epigenetics in epilepsy. Neurosci Lett 667:40-46.
[30] Kobow K, El-Osta A, Blümcke I. 2013. The methylation hypothesis of pharmacoresistance in epilepsy. Epilepsia 54 Suppl 2:41-7.
[31] Kumar S, Shanker OR, Banerjee J, Tripathi M, Chandra PS, Dixit AB. 2023. Epigenetics in epilepsy. Prog Mol Biol Transl Sci 198:249-269.
[32] Park MH, Kar RK, Banka S, Ziegler A, Chung WK. 2022. Post-translational formation of hypusine in eIF5A: implications in human neurodevelopment. Amino Acids 54:485-499.
[33] Alessandro D, Federico B. 2016. Post-translational modifications in neurodegeneration. AIMS Biophysics 3:27-49.
[34] Borgo C, D'Amore C, Sarno S, Salvi M, Ruzzene M. 2021. Protein kinase CK2: a potential therapeutic target for diverse human diseases. Signal Transduct Target Ther 6:183.
[35] Gągało I, Rusiecka I, Kocić I. 2015. Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome? Curr Neuropharmacol 13:836-44.
[36] Liu J, Schenker M, Ghiasvand S, Berdichevsky Y. 2019. Kinase Inhibitors with Antiepileptic Properties Identified with a Novel in Vitro Screening Platform. Int J Mol Sci 20.
[37] Mueller BK, Mack H, Teusch N. 2005. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 4:387-98.

[38] Pernice HF, Schieweck R, Kiebler MA, Popper B. 2016. mTOR and MAPK: from localized translation control to epilepsy. BMC Neurosci 17:73.
[39] Pearson-Smith JN, Patel M. 2017. Metabolic Dysfunction and Oxidative Stress in Epilepsy. Int J Mol Sci 18.
[40] Baraban SC. 2007. Emerging epilepsy models: insights from mice, flies, worms and fish. Curr Opin Neurol 20:164-8.
[41] Löscher W, Howe CL. 2022. Molecular Mechanisms in the Genesis of Seizures and Epilepsy Associated With Viral Infection. Front Mol Neurosci 15:870868.
[42] Stewart AM, Desmond D, Kyzar E, Gaikwad S, Roth A, Riehl R, Collins C, Monnig L, Green J, Kalueff AV. 2012. Perspectives of zebrafish models of epilepsy: what, how and where next? Brain Res Bull 87:135-43.
[43] Fischer FP, Karge RA, Weber YG, Koch H, Wolking S, Voigt A. 2023. Drosophila melanogaster as a versatile model organism to study genetic epilepsies: An overview. Front Mol Neurosci 16:1116000.
[44] Yang Y, Frankel WN. 2004. Genetic approaches to studying mouse models of human seizure disorders. Adv Exp Med Biol 548:1-11.
[45] Bizière K, Chambon JP. 1987. [Animal models of epilepsy and experimental seizures]. Rev Neurol (Paris) 143:329-40.
[46] Khamis ZI, Sarker DB, Xue Y, Al-Akkary N, James VD, Zeng C, Li Y, Sang QA. 2023. Modeling Human Brain Tumors and the Microenvironment Using Induced Pluripotent Stem Cells. Cancers (Basel) 15.
[47] Bulnes S, Murueta-Goyena A, Lafuente JV. 2021. Differential exposure to N-ethyl N-nitrosourea during pregnancy is relevant to the induction of glioma and PNSTs in the brain. Neurotoxicol Teratol 86:106998.
[48] Wang Y, Yang J, Zheng H, Tomasek GJ, Zhang P, McKeever PE, Lee EY, Zhu Y. 2009. Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. Cancer Cell 15:514-26.
[49] Khoshkhoo S, Wang Y, Chahine Y, Erson-Omay EZ, Robert SM, Kiziltug E, Damisah EC, Nelson-Williams C, Zhu G, Kong W, Huang AY, Stronge E, Phillips HW, Chhouk BH, Bizzotto S, Chen MH, Adikari TN, Ye Z, Witkowski T, Lai D, Lee N, Lokan J, Scheffer IE, Berkovic SF, Haider S, Hildebrand MS, Yang E, Gunel M, Lifton RP, Richardson RM, Blümcke I, Alexandrescu S, Huttner A, Heinzen EL, Zhu J, Poduri A, DeLanerolle N, Spencer DD, Lee EA, Walsh CA, Kahle KT. 2023. Contribution of Somatic Ras/Raf/Mitogen-Activated Protein Kinase Variants in the Hippocampus in Drug-Resistant Mesial Temporal Lobe Epilepsy. JAMA Neurol 80:578-587.
[50] Grote A, Schoch S, Becker AJ. 2015. Temporal lobe epilepsy: a unique window into living human brain epigenetic gene regulation. Brain 138:509-11.
[51] Shanker OR, Kumar S, Dixit AB, Banerjee J, Tripathi M, Sarat Chandra P. 2023. Epigenetics of neurological diseases. Prog Mol Biol Transl Sci 198:165-184.
[52] Caudle WM, Pan S, Shi M, Quinn T, Hoekstra J, Beyer RP, Montine TJ, Zhang J. 2008. Proteomic identification of proteins in the human brain: Towards a more comprehensive understanding of neurodegenerative disease. Proteomics Clin Appl 2:1484-97.
[53] Kar RK, Bhat PJ. 2021. MTH1 and cellular heterogeneity play the key role in galactose mediated signaling of the GAL genetic switch to utilize the disaccharide melibiose in yeast. . bioRxiv doi:https://doi.org/10.1101/2021.06.16.448739:2021.06. 16.448739.
[54] Kar RK, Kharerin H, Padinhateeri R, Bhat PJ. 2017. Multiple Conformations of Gal3 Protein Drive the Galactose-Induced Allosteric Activation of the GAL Genetic Switch of Saccharomyces cerevisiae. J Mol Biol 429:158-176.

[55] Kar RK, Qureshi MT, DasAdhikari AK, Zahir T, Venkatesh KV, Bhat PJ. 2014. Stochastic galactokinase expression underlies GAL gene induction in a GAL3 mutant of Saccharomyces cerevisiae. Febs j 281:1798-817.
[56] Das Adhikari AK, Qureshi MT, Kar RK, Bhat PJ. 2014. Perturbation of the interaction between Gal4p and Gal80p of the Saccharomyces cerevisiae GAL switch results in altered responses to galactose and glucose. Mol Microbiol 94:202-17.
[57] Lemke JR, Riesch E, Scheurenbrand T, Schubach M, Wilhelm C, Steiner I, Hansen J, Courage C, Gallati S, Bürki S, Strozzi S, Simonetti BG, Grunt S, Steinlin M, Alber M, Wolff M, Klopstock T, Prott EC, Lorenz R, Spaich C, Rona S, Lakshminarasimhan M, Kröll J, Dorn T, Krämer G, Synofzik M, Becker F, Weber YG, Lerche H, Böhm D, Biskup S. 2012. Targeted next generation sequencing as a diagnostic tool in epileptic disorders. Epilepsia 53:1387-98.
[58] Van Loo KMJ, Carvill GL, Becker AJ, Conboy K, Goldman AM, Kobow K, Lopes-Cendes I, Reid CA, van Vliet EA, Henshall DC. 2022. Epigenetic genes and epilepsy - emerging mechanisms and clinical applications. Nat Rev Neurol 18:530-543.
[59] Vashishta A, Slomnicki LP, Pietrzak M, Smith SC, Kolikonda M, Naik SP, Parlato R, Hetman M. 2018. RNA Polymerase 1 Is Transiently Regulated by Seizures and Plays a Role in a Pharmacological Kindling Model of Epilepsy. Mol Neurobiol 55:8374-8387.
[60] Pushkar Malakar* NS, Bandana Chakravarti, Didhiti Singha, Meghna Mondal, Rajesh Kumar Kar. 2023. A possible novel therapeutic targets of Selinexor in acute lymphoblastic leukemia: a comprehensive review. J Clin Transl Res 2023; 9(6):23-00088 9:9.
[61] Malakar P, Shukla S, Mondal M, Kar RK, Siddiqui JA. 2024. The nexus of long noncoding RNAs, splicing factors, alternative splicing and their modulations. RNA Biol 21:1-20.
[62] Singha D, Mondal M, Ghosh D, Choudhury D, Chakravarti B, Kar RK, Malakar P. 2024. The role of alternative splicing and splicing factors in diabetes: Current status and future perspectives. WIREs RNA 15:e1831.
[63] Vezzani A, French J, Bartfai T, Baram TZ. 2011. The role of inflammation in epilepsy. Nat Rev Neurol 7:31-40.
[64] Vuong CK, Black DL, Zheng S. 2016. The neurogenetics of alternative splicing. Nat Rev Neurosci 17:265-81.
[65] Boddu PC, Gupta A, Roy R, De La Pena Avalos B, Herrero AO, Neuenkirchen N, Zimmer J, Chandhok N, King D, Nannya Y, Ogawa S, Lin H, Simon M, Dray E, Kupfer G, Verma AK, Neugebauer KM, Pillai MM. 2023. Transcription elongation defects link oncogenic splicing factor mutations to targetable alterations in chromatin landscape. bioRxiv doi:10.1101/2023.02.25.530019.
[66] Malakar P, Shilo A, Mogilevsky A, Stein I, Pikarsky E, Nevo Y, Benyamini H, Elgavish S, Zong X, Prasanth KV, Karni R. 2017. Long Noncoding RNA MALAT1 Promotes Hepatocellular Carcinoma Development by SRSF1 Upregulation and mTOR Activation. Cancer Res 77:1155-1167.
[67] Waddell J, Banerjee A, Kristian T. 2021. Acetylation in Mitochondria Dynamics and Neurodegeneration. Cells 10.
[68] Yau TY, Molina O, Courey AJ. 2020. SUMOylation in development and neurodegeneration. Development 147.
[69] Pradhan AK, Emdad L, Das SK, Sarkar D, Fisher PB. 2017. The Enigma of miRNA Regulation in Cancer. Adv Cancer Res 135:25-52.
[70] Khan R, Chatterjee A, Ghosh H, Kapoor S, Ray S. 2019. Phytochemicals as Anticancer Drugs: Targeting the Microtubular Network of Cancer Cells, p 57-67. *In* Kumar S, Egbuna C (ed), Phytochemistry: An in-silico and in-vitro Update: Advances in

Phytochemical Research doi:10.1007/978-981-13-6920-9_3. Springer Singapore, Singapore.
[71] Nemec CM, Singh AK, Ali A, Tseng SC, Syal K, Ringelberg KJ, Ho YH, Hintermair C, Ahmad MF, Kar RK, Gasch AP, Akhtar MS, Eick D, Ansari AZ. 2019. Noncanonical CTD kinases regulate RNA polymerase II in a gene-class-specific manner. Nat Chem Biol 15:123-131.
[72] Schick V, Majores M, Fassunke J, Engels G, Simon M, Elger CE, Becker AJ. 2007. Mutational and expression analysis of CDK1, cyclinA2 and cyclinB1 in epilepsy-associated glioneuronal lesions. Neuropathol Appl Neurobiol 33:152-62.
[73] Sun J, Nan G. 2017. The extracellular signal-regulated kinase 1/2 pathway in neurological diseases: A potential therapeutic target (Review). Int J Mol Med 39:1338-1346.
[74] Chang P, Terbach N, Plant N, Chen PE, Walker MC, Williams RS. 2013. Seizure control by ketogenic diet-associated medium chain fatty acids. Neuropharmacology 69:105-14.
[75] Cucchiara F, Pasqualetti F, Giorgi FS, Danesi R, Bocci G. 2020. Epileptogenesis and oncogenesis: An antineoplastic role for antiepileptic drugs in brain tumours? Pharmacol Res 156:104786.
[76] You G, Sha Z, Jiang T. 2012. The pathogenesis of tumor-related epilepsy and its implications for clinical treatment. Seizure 21:153-9.
[77] Perucca E. 2013. Optimizing antiepileptic drug treatment in tumoral epilepsy. Epilepsia 54 Suppl 9:97-104.
[78] Newton HB, Wojkowski J. 2024. Antiepileptic Strategies for Patients with Primary and Metastatic Brain Tumors. Curr Treat Options Oncol 25:389-403.
[79] van Breemen MS, Wilms EB, Vecht CJ. 2007. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 6:421-30.
[80] Maschio M, Dinapoli L, Zarabia A, Jandolo B. 2006. Issues related to the pharmacological management of patients with brain tumours and epilepsy. Funct Neurol 21:15-9.
[81] Hauff NS, Storstein A. 2023. Seizure Management and Prophylaxis Considerations in Patients with Brain Tumors. Curr Oncol Rep 25:787-792.